EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END
Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for a patent application covering its Nutriband AVERSA™ abuse deterrent transdermal technology Nutriband...
Nutriband (NASDAQ: NTRB, NTRBW), a pharmaceutical company with a special focus on transdermal technologies, today announced that it has selected IBN , a multifaceted financial news and publishing company...
Nutriband (NASDAQ: NTRB, NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has closed an $8.4 million private placement to fund the...
/PRNewswire/ -- The demand for abuse deterrent formulation technology is projected to grow due to growing misuse of drugs among the people. Growing demand for...
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END
Patent issuance expands U.S. patent portfolio for AVERSA™ transdermal abuse deterrent technology Orlando, FL – September 20, 2023 – Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of...
ORLANDO, FL / ACCESSWIRE / July 27, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) ("Nutriband" or the "Company") announced today that its Board of Directors has approved and declared a 7:6 forward...
ORLANDO, FL / ACCESSWIRE / July 26, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that it has received the Final Judgment in favor of the company, effectively allowing the company to...